Is CSII the answer to insulin allergy?
Patients with type 2 diabetes who suffer from insulin allergy may benefit from short-term continuous subcutaneous insulin infusion (CSII) to reduce their sensitivity, Chinese researchers say.
Five patients with confirmed insulin allergy were put on insulin pumps for three days. The pumps used a short-action insulin preparation that was diluted ten times.
The basal rate of diluted insulin began with 0.01IU/h of insulin and had a speed of 0.24IU/h